Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 16/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 10/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 4/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412858 | 0.93 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434006 | 0.93 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15433996 | 0.91 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434022 | 0.91 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15433997 | 0.91 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15412806 | 0.90 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15433992 | 0.89 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434038 | 0.89 | FGFR1 (0.82) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434005 | 0.89 | FGFR4 (0.87) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL23314978 | 0.89 | FGFR4 (0.92) | FGFR4FGFR1FGFR2FGFR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250283178-A1 | FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE | 3N DIAGNOSTICS LTD. (GB) | 2025-09-11 | — | — | US | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| EP-4519292-A2 | FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE | 3N Diagnostics Ltd. (GB) | 2025-03-12 | — | — | EP | claimed |
| US-20240100053-A1 | PHARMACEUTICAL COMPOSITION | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2024-03-28 | — | — | US | claimed |
| WO-2023214358-A2 | FOXC1 EXPRESSION AS A COMPLEMENTARY DIAGNOSTIC ASSAY FOR PREDICTING EFFICACY OF ONCOLOGY DRUGS AND DRUG COMBINATION REGIMENS AND METHODS FOR USE | 3N DIAGNOSTICS LTD. (GB) | 2023-11-09 | — | — | WO | claimed |
| EP-4262984-A2 | METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS | Genecentric Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-11768205-B2 | Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-09-26 | — | — | US | claimed |
| EP-3636773-B1 | N-CADHERIN AND FGFR1 AND/OR FGFR4 FOR USE IN PREDICTING THE RESPONSE OF PATIENTS TO A LUNG CANCER TREATMENT AND METHOD AND KIT BASED ON SAID USE | FUNDACION DE INVESTIG HOSPITAL 12 DE OCTUBRE (ES) | 2023-08-23 | — | — | EP | claimed |
| US-20230243813-A1 | METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. | 2023-08-03 | — | — | US | claimed |
| US-11408038-B2 | N-cadherin and FGFR1 and/or FGFR4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use | FUNDACIÓN DE INVESTIGACIÓN HOSPITAL 12 DE OCTUBRE | 2022-08-09 | — | — | US | claimed |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | PHARMACOSMOS HOLDING A/S (DK) | 2022-08-04 | — | — | US | claimed |
| WO-2022154044-A1 | PHARMACEUTICAL COMPOSITION | 地方独立行政法人東京都健康長寿医療センター | 2022-07-21 | — | — | WO | claimed |
| CN-114761009-A | Targeted treatment of cancer with deregulated fibroblast growth factor receptor signaling | G1治疗公司 | 2022-07-15 | — | — | CN | claimed |
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2022-05-12 | — | — | US | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| US-20190192522-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2019-06-27 | — | — | US | claimed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | claimed |
| EP-3236943-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. (US) | 2017-11-01 | — | — | EP | claimed |
| WO-2016105582-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | NUNN PHILIP A (US) | 2016-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143049-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | MAP3K20, MAP3K10, DCK | FGFR4 720/4885FGFR1 489/4885FGFR2 734/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | FGFR4 4248/4885FGFR1 3506/4885FGFR2 3828/4885 |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | FGFR1, FGFR2, FGFR3 | FGFR4 4/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | FGFR4 2426/4885FGFR1 2329/4885FGFR2 1687/4885 |
| US-20240100053-A1 | PHARMACEUTICAL COMPOSITION | FGFR4, FIBP, FGFR3 | FGFR4 1/4885FGFR1 7/4885FGFR2 5/4885 |
| US-11768205-B2 | Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin | STUB1, ACP1, UBQLN2 | FGFR4 4110/4885FGFR1 3711/4885FGFR2 3516/4885 |
| US-20190192522-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, FGFR4, CDKL4 | FGFR4 2/4885FGFR1 4/4885FGFR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.